Q-omics provides the consensus-scored SEPHS1P1 profile across patient tissues and cancer cell-line models. SEPHS1P1 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, SEPHS1P1 is differentially expressed in 7, with the highest sampling consensus in CHOL. Additionally, SEPHS1P1 RNA expression shows 13,681 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UCEC, CHOL, and UVM as cancer lineages where SEPHS1P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SEPHS1P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SEPHS1P1 survival associations across molecular data types. SEPHS1P1 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SEPHS1P1 RNA expression–survival associations across cancer types. High SEPHS1P1 expression shows unfavorable associations in UCEC, THCA and LUAD, but favorable associations in ACC, LUSC and PAAD. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify UCEC as the clearest survival context for SEPHS1P1 RNA expression.
This table summarizes SEPHS1P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in CHOL for RNA.
This table ranks reproducible tumor–normal expression differences for SEPHS1P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SEPHS1P1 shows lower tumor expression in KICH and KIRC and higher tumor expression in CHOL, COAD, LIHC and BRCA. The CHOL box plot shows higher SEPHS1P1 RNA expression in tumor versus normal tissue (log2 FC = +0.246, t-test p = .001).
This table shows molecular features associated with SEPHS1P1 in patient tissues and cancer cell lines. In patient samples, SEPHS1P1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
